10.6 Comorbid Conditions & Their Interaction With Cancer Treatment
Key Takeaways
- Most patients with cancer over age 65 carry at least one significant comorbidity, and comorbidity burden predicts treatment tolerance and survival independently of cancer stage.
- Trastuzumab-associated cardiac dysfunction is usually reversible with drug interruption, whereas anthracycline cardiomyopathy is cumulative and largely irreversible.
- Hepatitis B surface antigen and core antibody must be checked before rituximab or other B-cell-depleting therapy, because reactivation can cause fulminant hepatic failure and requires antiviral prophylaxis.
- Dexamethasone given with chemotherapy predictably raises blood glucose for 2 to 3 days after each dose, and PI3K and mTOR inhibitors cause on-target hyperglycemia requiring proactive management.
- Patients with pre-existing autoimmune disease can receive checkpoint inhibitors, but flare rates are substantial and require explicit risk discussion and rheumatology co-management.
10.6 Comorbid Conditions & Their Interaction With Cancer Treatment
Blueprint focus: ONCC Domain II.N — Interrelationship between disease, treatment, and comorbid conditions. The blueprint asks you to treat the whole patient, because comorbidity determines what treatment is deliverable and what will actually kill the patient.
Why Comorbidity Drives Outcome
The majority of adults diagnosed with cancer over the age of 65 have at least one significant chronic condition, and many have several. Comorbidity burden predicts treatment tolerance, dose intensity actually delivered, hospitalization, and overall survival independently of cancer stage. For patients with early-stage cancers and heavy comorbidity, competing causes of death may exceed the cancer's own risk — which reframes the entire treatment discussion.
The interaction runs in three directions:
- Comorbidity constrains cancer treatment — reduced creatinine clearance forecloses cisplatin; reduced ejection fraction forecloses anthracyclines.
- Cancer treatment destabilizes comorbidity — corticosteroids wreck glycemic control; androgen deprivation accelerates osteoporosis and metabolic syndrome.
- Cancer itself alters comorbidity management — anorexia and weight loss can make a diabetic patient hypoglycemic on unchanged medication, and hepatic metastases change warfarin control.
Cardiovascular Disease and Cardio-Oncology
| Agent | Cardiac effect | Reversibility | Monitoring |
|---|---|---|---|
| Anthracyclines | Dose-dependent cardiomyopathy | Largely irreversible | Baseline and serial LVEF; respect cumulative dose ceilings; consider dexrazoxane |
| Trastuzumab and other HER2 agents | Left ventricular dysfunction | Usually reversible with interruption | LVEF at baseline and every 3 months during therapy |
| VEGF inhibitors (bevacizumab, sunitinib, sorafenib) | Hypertension, arterial thromboembolism, cardiomyopathy | Variable | Blood pressure at every visit; treat hypertension rather than stopping the drug when possible |
| Fluorouracil and capecitabine | Coronary vasospasm and angina | Reversible on discontinuation | Investigate chest pain; rechallenge is risky |
| Chest radiation | Accelerated coronary disease, valvular disease, pericardial constriction | Progressive | Long-term cardiovascular risk management |
| Immune checkpoint inhibitors | Myocarditis — rare but with high mortality | Requires immediate high-dose steroids | Troponin and ECG for any cardiac symptom |
| Androgen deprivation therapy | Metabolic syndrome, cardiovascular events | Modifiable | Lipids, glucose, blood pressure, exercise |
Practical rules: treat hypertension aggressively rather than abandoning an effective VEGF inhibitor; continue guideline-directed heart failure therapy with ACE inhibitors or ARBs and beta-blockers through cancer treatment; involve cardio-oncology before the ejection fraction falls, not after.
Diabetes and Glycemic Control
- Dexamethasone given with chemotherapy causes a predictable postprandial glucose rise that peaks and persists for 2 to 3 days after each dose. Anticipate it: adjust insulin proactively on steroid days rather than reacting to a glucose of 400 mg/dL.
- PI3K inhibitors (alpelisib) and mTOR inhibitors (everolimus) cause on-target hyperglycemia — hyperglycemia is the expected pharmacologic consequence of the mechanism, not an idiosyncratic reaction. Screen HbA1c and fasting glucose before starting, and treat with metformin first-line.
- Immune checkpoint inhibitors can cause fulminant autoimmune type 1 diabetes with diabetic ketoacidosis as the presenting event; this is permanent and requires lifelong insulin.
- Hypoglycemia risk rises with anorexia, vomiting, mucositis, or a shrinking insulin-antagonizing tumor burden — sulfonylureas in particular should be reviewed when intake falls.
- Hyperglycemia worsens infection risk and wound healing, so glycemic control is not a distraction from cancer care.
Renal and Hepatic Impairment
Renal. Calculate creatinine clearance rather than reading serum creatinine, since sarcopenic patients have misleadingly normal values. Cisplatin is generally avoided below a clearance of roughly 50 to 60 mL/min; carboplatin is dosed directly from GFR by the Calvert formula; high-dose methotrexate requires adequate clearance plus alkalinization and leucovorin rescue; several direct oral anticoagulants and many targeted agents require renal adjustment. Nephrotoxic combinations — cisplatin plus an aminoglycoside plus contrast — should be sequenced apart.
Hepatic. Anthracyclines, vinca alkaloids, and taxanes are biliary-cleared and require reduction based on bilirubin. Baseline hepatitis serologies matter (below). Drug-induced liver injury from tyrosine kinase inhibitors and checkpoint inhibitors requires that a rising transaminase be worked up rather than assumed to be progression.
Autoimmune Disease and Immunotherapy
A pre-existing autoimmune condition is not an absolute contraindication to checkpoint inhibition, but flare rates are substantial and can be severe.
- Highest concern: inflammatory bowel disease, myasthenia gravis, multiple sclerosis, and any condition requiring more than roughly 10 mg of prednisone daily.
- Baseline immunosuppression above physiologic replacement may blunt efficacy.
- Manage jointly with rheumatology, gastroenterology, or neurology, document the risk discussion explicitly, and monitor more intensively than usual.
- Solid organ transplant recipients face a real risk of graft rejection with checkpoint inhibitors and require transplant nephrology or hepatology co-management.
Chronic Infection Screening Before Immunosuppression
| Infection | When to screen | Consequence if missed |
|---|---|---|
| Hepatitis B (surface antigen and core antibody) | Before rituximab or other B-cell-depleting therapy, HSCT, and high-dose corticosteroids | Reactivation causing fulminant hepatic failure; requires entecavir or tenofovir prophylaxis |
| Hepatitis C | Broadly, before immunosuppression | Progression of liver disease |
| HIV | Broadly; affects regimen choice and drug interactions | Missed opportunistic infection prophylaxis |
| Tuberculosis | Before prolonged corticosteroids, TNF inhibitors used for immune-related toxicity | Reactivation |
| Strongyloides | Patients from endemic areas before corticosteroids | Hyperinfection syndrome, often fatal |
Pneumocystis jirovecii prophylaxis is indicated with prolonged corticosteroid exposure — commonly the equivalent of 20 mg of prednisone daily for 4 weeks or more — and with certain regimens such as temozolomide with radiation and purine analogs.
Bone Health
Multiple cancer treatments accelerate bone loss: aromatase inhibitors, androgen deprivation therapy, corticosteroids, and premature menopause from chemotherapy or oophorectomy. Obtain baseline DEXA, supplement calcium and vitamin D, encourage weight-bearing exercise, and add an antiresorptive agent when the T-score or fracture risk warrants it. Before starting a bisphosphonate or denosumab, arrange dental evaluation to reduce osteonecrosis of the jaw risk.
Polypharmacy
Older adults with cancer commonly take five or more chronic medications before oncology adds antiemetics, growth factors, analgesics, anticoagulants, and antimicrobials.
- Reconcile the complete list — prescriptions, over-the-counter drugs, herbals, and supplements — at every visit.
- Screen for the interaction classes that matter most: CYP3A4 inducers and inhibitors, QT-prolonging combinations, acid suppression with pH-dependent oral agents, anticoagulant interactions, and additive sedation.
- Apply Beers criteria in older adults and deprescribe what no longer serves the patient's goals — a statin for primary prevention in a patient with a 4-month prognosis is a burden, not a benefit.
- Involve an oncology pharmacist; medication review is one of the highest-yield interventions available in this population.
A 58-year-old woman with diffuse large B-cell lymphoma is scheduled to begin R-CHOP. Which pretreatment screening test is essential to prevent a potentially fatal complication of the rituximab component?
A patient with type 2 diabetes on metformin begins a chemotherapy regimen that includes dexamethasone 12 mg on day 1 of each cycle. Her home glucose readings rise to 320 to 380 mg/dL on days 1 through 3 of each cycle, then return to baseline. What is the most appropriate management?
A 66-year-old man with metastatic melanoma also has ulcerative colitis in remission on mesalamine. His oncologist proposes a PD-1 inhibitor. How should the nurse practitioner counsel him?